Brief: Cipher Pharmaceuticals Receives Health Canada Approval Of Xydalba
10/09/2018 21:04
Sept 10 (Reuters) - Cipher Pharmaceuticals Inc CPH.TO :
* CIPHER PHARMACEUTICALS RECEIVES HEALTH CANADA APPROVAL OF
XYDALBA™ (DALBAVANCIN HYDROCHLORIDE)
Source text for Eikon: ID:nCNWX55Lba
Further company coverage: CPH.TO
(Reuters.Briefs@thomsonreuters.com)
Recent news on Cipher Pharmaceuticals
See all newsBrief: Cipher Pharmaceuticals Receives Favourable Decision Confirming Arbitration Award
Canada's Cipher Pharma Q2 revenue falls on lower Natroba sales amid reduced Medicaid coverage
Canada Research Roundup: Altius Minerals, Cipher Pharmaceuticals, Suncor Energy
Canada's Cipher Pharmaceuticals Q1 net income jumps 135% on lower costs
Brief: Cipher Pharmaceuticals Q1 Net Income USD 6.163 Million